News from Wasatch Pharmaceutical (OTCBB: WSCH) is hard to come by lately. Gary Heesch, CEO of Wasatch, doesn't buy the idea that a press release every day is
productive. He feels "it is usually perceived as an effort to over- promote the stock." But what about the future of WSCH? Why should anyone buy or hold their stock with no news?
Mr. Heesch feels that past news releases and their record of Company accomplishments speak for themselves. For example, Wasatch, now in its 18th year of research, has produced skin care
products for the treatment of most common skin disorders. This puts them years ahead of the competition.
In the last 12 months, WSCH has addressed a whole new dimension in preparation for launching its products into the worldwide marketplace, so that millions of people will finally have access to therapies that
allow them to remedy their skin disorders and live more normal lives. This preparation involved:
(1) A new management team with impressive individual records of creating billions of dollars in revenue for Oracle, Bausch & Lomb, and Warner Lambert.
(2) The establishment of a new AISC Distribution Center that is fully inventoried with products ready for shipment.
(3) Establishing beautiful corporate offices separate from the company's clinic.
(4) Relocation of the American Institue of Skin Care clinic to a facility designed to be the prototype for future clinics.
To cap off the last 12 months, patents were filed for five new products that will be packaged and ready for release to physicians and hospitals this year. All of these accomplishments translate into a variety of
activites and relationships that will insure the growth and stability of WSCH.
When pressed to reveal this year's plans, Mr. Heesch wants to reserve the substance of these activities until they are completed and tucked away. He did say that existing activities and plans include the
acquisition of existing medical clinics, ongoing discussion for foreign licensing, conversations with groups of physicians that can represent as many as 2,000 physicians converting their patients to Wasatch
products for their skin care problems, and also a possible merger that will expand WSCH's sphere of influence in the medical community.
As these activities come to fruition, they will be disclosed to WSCH shareholders and the public in detail. Unlike many companies struggling with today's economy, Wasatch Pharmaceutical is alive and well
and working towards a productive future.
Stay tuned for plenty more to come from WSCH.